A proposed role for excitotoxicity in glaucoma

Journal of Glaucoma

Volumn 7, Issue 1, 1998, Pages 62-67

  Dreyer, Evan Benjamin ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Glaucoma; Glutamate; NMDA; Retinal ganglion cells

Indexed keywords

GLUTAMIC ACID;

ARTICLE; GLAUCOMA; HUMAN; NEUROTOXICITY; PRIORITY JOURNAL;

EID: 0031937195     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/00061198-199802000-00012     Document Type: Article

References (43)

1. Hiller R, Kahn HA. Blindness from glaucoma. Am J Ophthal 1975; 80:62-9.
2. Quigley HA, Addicks EM. Chronic experimental glaucoma in primates. II. Effect of extended intraocular pressure elevation on optic nerve head and axonal transport. Invest Ophthalmol Vis Sci 1980; 19:137-52.
3. Radius RL, Anderson DR. Rapid axonal transport in primate optic nerve. Distribution of pressure-induced interruption. Arch Ophthalmol 1981;99:650-4.
4. Quigley HA, Flower RW, Addicks EM, McLeod DS. The mechanism of optic nerve damage in experimental acute intraocular pressure elevation. Invest Ophthalmol Vis Sci 1980;19:505-17.
5. Quigley HA, Addicks EM, Green WR, Maumenee AE. Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Arch Ophthalmol 1981;99:635-49.
6. Lucas DR, Newhouse JP. The toxic effect of sodium L-glutamate on the inner layers of the retina. Arch Ophthalmol 1957;58:193-201.
7. Siliprandi R, Canella R, Carmignoto G, Schiavo N, Zanellato A, Zanoni R, Vantini G. N-methyl-D-aspartate induced neurotoxicity in the adult rat retina. Vis Neurosci 1992;8:567-73.
8. Olney JW. Glutamate-induced retinal degeneration in neonatal mice: electron microscopy of the acutely evolving lesion. J Neuropathol Exp Neurol 1969;28:455-74.
9. Olney JW, Ho OL. Brain damage in infant mice following oral intake of glutamate, aspartate or cysteine. Nature 1970;227:609-11.
10. Lipton S. Prospects for clinically tolerated NMDA antagonists. Trends in Neuroscience 1993;16:527-32.
11. Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends in Pharmacologic Science 1990;11:379-87.
12. Rothman S, Olney J. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol 1986;19:105-11.
13. Olney JW, Price MT, Fuller TA, Labruyere J, Samson L, Carpenter M, Mahan K. The anti-excitotoxic effects of certain anasthetics, analgesics, and sedative-hypnotics. Neurosci Lett 1986;68:29-34.
14. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1:623-34.
15. Dreyer EB, Zhang D, Lipton SA. Transcriptional or translational inhibition blocks low dose NMDA-mediated cell death. Neuroreport 1995;6:942-4.
16. Dugan L, Sensi S, Canzoniero L, et al. Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-D-Aspartate. J Neurosci 1995;15:6377-88.
17. Manev M, Costa E, Wroblewski J, Guidotti P. Abusive stimulation of excitatory amino acid receptors: a strategy to limit neurotoxicity. FASEB J 1990;4:2789-96.
18. Szatkowsli M, Attwell D. Triggering and execution of neuronal death in brain ischemia; two phases of glutamate release by different mechanisms. Trends In Neuroscience 1994;17:359-365.
19. Quigley HA, Nickells RW, Pease ME, Kerrigan LA, Thibault DJ, Zack DJ. Retinal ganglion cell death in experimental monkey glaucoma and axotomy occurs by apoptosis. Invest Opthalmol Vis Sci 1995;36:774-86.
20. Bonfoco E, Krainc D, Ankarcrona M, Nicotera P, Lipton SA. Apoptosis and necrosis: two distinct events induced respectively by mild and intense insults with NMDA or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci USA 1995;92:7162-6.
21. Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA. Elevated glutamate in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol 1996;114:299-305.
22. Ambati J, Chalam KV, Chawla DK, et al. Elevated γ-aminobutyric acid glutamate and VEUF levels in the vitreons of patients with proliferative diabetic retinopathy. Arch Ophthalmol 1997; 115:1161-6.
23. McLoon SC. Response of astrocytes in the visual system to Wallerian degeneration: an immunohistochemical analysis of laminin and glial fibrillary acidic protein (GFAP). Exp Neurol 1986;91: 613-21.
24. Sucher NJ, Lei SZ, Lipton SA. Calcium channel antagonists attenuate NMDA receptor-mediated neurotoxicity of retinal ganglion cells in culture. Brain Res 1991;551:297-302.
25. Sucher NJ, Aizenmann E, Lipton SA. N-Methyl-D-Aspartate antagonists prevent kainate neurotoxicity in rat retinal ganglion cells in vitro. J Neurosci 1991;11:966-71.
26. Sucher NJ, Wong LA, Lipton SA. Redox modulation of NMDA receptor-mediated Ca2+ flux in mammalian central neurons. Neuroreport 1990;1:29-32.
27. Vorwerk CK, Lipton SA, Hyman BT, Sobel BA, Dreyer EB. Chronic low dose glutamate is toxic to retinal ganglion cells; toxicity blocked by memantine. Invest Ophthalmol Vis Sci 1996;37: 1618-24.
28. Hollmann M, Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci 1994;17:31-108.
29. Moriyoshi K, Masu M, Ishii T, Shigemoto R, Mizuno N, Nakamishi S. Molecular cloning and characterization of the rat NMDA receptor. Nature 1991;354:31-6.
30. Kutsuwada T, Kashiwabuchi N, Mori H, et al. Molecular diversity of the NMDA receptor channel. Nature 1992;358:36-41.
31. Johnson J, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987;325:529-31.
32. Hofmann F, Biel M, Flockerzi V. Molecular basis for Ca2+ channel diversity. Annu Rev Neurosci 1994;17:399-418.
33. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995;26:503-13.
34. Bormann J. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol 1989;166: 591-2.
35. Chen HSV, Pelligrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, Lipton SA. Open channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 1992;12: 4427-36.
36. Kornhuber J, Bormann J, Retz W, Hubers M, Riederer P. Memantine displaces [3H]MK-801 at therapeutic concentrations in post-mortem human frontal cortex. Eur J Pharmacol 1989;166:589-90.
37. Klockgether T, Loschmann P, Wullner U. New medical and surgical treatments for Parkinson's disease. Curr Opin Neurol 1994; 7:346-52.
38. Mosinger JL, Price MT, Bai HY, Xiao H, Wozniak DF, Olney JW. Blockade of both NMDA and non-NMDA receptors is required for optimal protection against ischemic neuronal degeneration in the in vivo adult mammalian retina. Exp Neurol 1991;113:10-7.
39. Hubert JP, Delumeau JC, Glowinski J, Premont J, Doble A. Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action. Br J Pharmacol 1994;113:261-7.
40. Malgouris C, Daniel M, Doble A. Neuroprotective effects of riluzole on N-methyl-D-aspartate- or veratridine-induced neurotoxicity in rat hippocampal slices. Neurosci Lett 1994;177:95-9.
41. Lipton SA, Choi YB, Pan ZH, et al. A redox-based mechanism for the neuroprotective neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 1993;364:626-31.
42. Dreyer EB, Kaiser PK, Offermann JT, Lipton SA. HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists. Science 1990;248:364-7.
43. Greenberg JH, Uematsu D, Araki N, Hickey WF, Reivich M. Cytosolic free calcium during focal cerebral ischemia and the effects of nimodipine on calcium and histologic damage. Stroke 1990;21: 72-7.